Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies

Alzheimer's Research and Therapy

Volumn 8, Issue 1, 2016, Pages

  Ivanoiu, Adrian ^a   Pariente, Jérémie ^b   Booth, Kevin ^c   Lobello, Kasia ^c   Luscan, Gerald ^c   Hua, Lisa ^c   Lucas, Prisca ^c   Styren, Scot ^c   Yang, Lingfeng ^c   Li, David ^c   Black, Ronald S ^c   Brashear, H Robert ^d   McRae, Thomas ^c  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CHU PURPAN   (France)

^c PFIZER INC   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alzheimer's disease; Amyloid beta; Amyloid related imaging abnormalities with edema or effusions vasogenic edema; Bapineuzumab; Immunotherapy

Indexed keywords

APOLIPOPROTEIN E4; BAPINEUZUMAB; APOLIPOPROTEIN E; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ANXIETY; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; CARDIOMYOPATHY; DIARRHEA; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GAIT DISORDER; GASTROENTERITIS; HEADACHE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; AGED; CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; APOLIPOPROTEINS E; FEMALE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 84978299770     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-016-0193-y     Document Type: Article

References (13)

1. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106-18. Erratum: Nat Rev Neurol. 2013. doi: 10.1038/nmeurol.2013.32.
2. Madeo J, Frieri M. Alzheimer's disease and immunotherapy. Aging Dis. 2013;4:210-20.
3. Singh S, Kushwah AS, Singh R, Farswan M, Kaur R. Current therapeutic strategy in Alzheimer's disease. Eur Rev Med Pharmacol Sci. 2012;16:1651-64.
4. Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013;8:36.
5. Alzheimer's Association. 2013 Alzheimer's disease facts and figures. 2013. http://www.alz.org/downloads/facts-figures-2013.pdf. Accessed 8 Dec 2015.
6. Tayeb HO, Murray ED, Price BH, Tarazi FI. Bapineuzumab and solanezumab for Alzheimer's disease: is the "amyloid cascade hypothesis" still alive? Expert Opin Biol Ther. 2013;13:1075-84.
7. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
8. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061-70.
9. Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367-85.
10. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group: phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
11. Panza F, Solfrizzi V, Imbimbo BP, Giannini M, Santamato A, Seripa D, et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. Expert Rev Neurother. 2014;14:973-86.
12. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387-403.
13. Blennow K, Hampel H, Zetterberg H. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology. 2014;39:189-201.